NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
38 trialsNCT07522151 2026-04-13
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 3 Not yet recruiting
NCT06256328 2026-03-13
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT05867121 2026-02-02
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04566380 2025-06-03
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT00651742 2024-09-19
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT02855125 2024-09-19
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
Taiho Oncology, Inc.
Phase 2 Completed
NCT05144854 2024-09-05
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT02454062 2024-09-04
A Trial of TAS-114 in Combination With S-1
Taiho Oncology, Inc.
Phase 1 Completed
NCT00072787 2024-09-03
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT00400023 2024-09-03
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT00651833 2024-09-03
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT00652054 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT00652561 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06194734 2024-03-07
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT04070313 2021-12-06
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
TTY Biopharm
Phase 2 Terminated
NCT02862535 2020-12-24
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences
Phase 1 Terminated
NCT00770874 2019-06-21
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT02359058 2018-01-24
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01610479 2017-08-04
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02867397 2016-08-15
Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
Disphar International B.V.
Phase 1 Completed
NCT00602745 2016-05-26
S-1 Pancreas
Sanofi
Phase 3 Terminated
NCT00553696 2015-03-13
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Pfizer
Phase 1 Completed
NCT01388790 2013-11-20
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00816543 2012-12-18
Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
Sanofi
Phase 2 Completed
NCT00569335 2012-11-02
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00569699 2012-11-02
Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00569790 2012-11-02
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00891332 2012-01-18
Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT00152217 2011-07-07
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00202969 2011-07-07
Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00960349 2011-06-14
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
AstraZeneca
Phase 1 Completed
NCT00479076 2011-01-26
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
Sanofi
Phase 1 Completed